<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03825315</url>
  </required_header>
  <id_info>
    <org_study_id>1820201</org_study_id>
    <nct_id>NCT03825315</nct_id>
  </id_info>
  <brief_title>DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis</brief_title>
  <official_title>A Phase II, Prospective, Randomized, Double-Blind, Multi-center, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revance Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revance Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel group, multi-center trial of
      a single administration of DaxibotulinumtoxinA (DAXI) (high-dose; low-dose) for injection
      versus placebo for the management of Plantar Fasciitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 150 subjects, recruited from approximately 20 study centers in the United
      States (US) will be randomized to DAXI (HIGH-dose; LOW-dose) or placebo group, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 31, 2018</start_date>
  <completion_date type="Actual">June 4, 2020</completion_date>
  <primary_completion_date type="Actual">June 4, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomly assigned to 1 of 3 treatment groups: DAXI for injection LOW dose, DAXI for injection HIGH dose, Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the Numeric Pain Rating Scale (NPRS) score</measure>
    <time_frame>Week 8</time_frame>
    <description>Change from baseline in the Numeric Pain Rating Scale (NPRS) score (Scale Range: 0 {No pain} to 10 {Worst pain imaginable})</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Foot Function Index (FFI)</measure>
    <time_frame>All post treatment time points (approximately 6 months)</time_frame>
    <description>Change from baseline in Foot Function Index (FFI) (Pain Sub-Scale Range: 0 {No pain} to 10 {Worst pain imaginable}, Disability Sub-Scale Range: 0 {No difficulty} to 10 {So difficult unable to do so}, Activity Limitation Sub-Scale Range: 0 {None of the time} to 10 {All of the time})</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Moderate improvement on the Clinical Global Impression of Change (CGIC)</measure>
    <time_frame>All post treatment time points (approximately 6 months)</time_frame>
    <description>Proportion of subjects with improvement on the Clinical Global Impression of Change (CGIC) over time</description>
  </other_outcome>
  <other_outcome>
    <measure>Improvement on the the Patient Global Impression of Change (PGIC)</measure>
    <time_frame>All post treatment time points (approximately 6 months)</time_frame>
    <description>Proportion of subjects with improvement on the Patient Global Impression of Change (PGIC) over time</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Plantar Fasciitis</condition>
  <arm_group>
    <arm_group_label>DAXI for Injection: LOW Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LOW Dose Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAXI for Injection: HIGH Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIGH Dose Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DAXI for Injection: LOW Dose</intervention_name>
    <description>DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.</description>
    <arm_group_label>DAXI for Injection: LOW Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DAXI for Injection: HIGH Dose</intervention_name>
    <description>DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.</description>
    <arm_group_label>DAXI for Injection: HIGH Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent, including authorization to release health information.

          -  Male or female subjects 18 to 65 years of age with diagnosis of unilateral plantar
             fasciitis.

          -  Persistent heel pain.

          -  Women of child bearing potential must have a negative pregnancy test at Screening and
             Injection Visits and must use an effective method of contraception during the course
             of the study.

        Exclusion Criteria:

          -  Previous injection of botulinum toxin in the lower extremities or feet.

          -  Previously suffered a partial or full thickness tear or surgery of the plantar fascia
             within the 5 years preceding participation in the investigation.

          -  Pregnant, nursing, or planning a pregnancy during the study.

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within the last 30 days prior to first visit.

          -  Any condition or situation which, in the Investigator's opinion, puts the subject at
             significant risk, could confound the trial results, or may interfere significantly
             with the subject's participation in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Rubio, MD</last_name>
    <role>Study Director</role>
    <affiliation>Revance Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aung Foot Health Clinic</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacramento Foot and Ankle Center, Inc</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Foot Care</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Foot and Ankle</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Foot Care</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Foot and Ankle Foundation</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA Podiatry Group</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Podiatry 1st</name>
      <address>
        <city>Belleville</city>
        <state>Illinois</state>
        <zip>62226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosalind Franklin University of Medicine &amp; Science</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas Institute of Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211-1358</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Foot &amp; Ankle Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research International</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Institute of Neurology and Headache</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hermann Drive Research Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Futuro Clinical Trials, LLC</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strash Foot and Ankle Care</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Podiatry Group of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Foot and Ankle, LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DAXI for injection,</keyword>
  <keyword>Plantar Fasciitis,</keyword>
  <keyword>Heel Pain,</keyword>
  <keyword>BotulinumtoxinA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Plantar</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

